NCT05514067Completed
Electroacupuncture for Heart Protection: Clinical Application in Patients Undergoing Cardiac Bypass Surgery
Source: ClinicalTrials.gov · Last updated 29 Oct 2024
Brief summary (registry, in English)
Coronary artery disease (CAD) is the leading cause of death and disability in Singapore and worldwide. Many patients with multi-vessel CAD require surgical revascularisation by coronary artery bypass graft (CABG) surgery, and are at risk of postsurgical complications such as peri-operative myocardial injury (PMI), left ventricular dysfunction, heart failure, and death. This risk is particularly important given that the aging population, and increased prevalence of co-morbidities (diabetes, hypertension, renal failure) and complexity of cardiac surgery, mean that higher risk patients are undergoing CABG surgery. As such, new treatment strategies are required to protect the heart during CABG surgery in order to improve health outcomes in patients with CAD. In this regard, a number of animal studies have demonstrated that electroacupuncture (EA) at cardiac-related acupoints can protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). However, the mechanisms underlying the beneficial effect of EA, and whether EA can protect the heart against PMI in patients undergoing CABG surgery are not known. Therefore, in this research proposal, the investigators will investigate whether EA at cardiac-related acupoints can protect the heart against PMI during CABG surgery, and the investigators will elucidate the mechanisms underlying the cardioprotective effects of EA.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 16 May 2022
- Start date
- 9 Jul 2020
- Primary completion date
- 14 Nov 2023
- Lead sponsor
- National Heart Centre Singapore
- Diseases
- Coronary artery disease
- NCT number
- NCT05514067
What you commit to
- Study type: Interventional
- Participants enrolled: 10
- From 9 Jul 2020 to the primary completion date, 14 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with recent myocardial infarction (\<30 days)
Lab values
- Patients with significant hepatic dysfunction (If available, INR\>2)
- Patients with significant pulmonary disease (If available, FEV1\<40% predicted). - Patients with known renal failure with a GFR≤30 mL/min/1.73 m2.
Other
- Patients recruited into another study which may impact on this study.
Who the study is looking for
- Patients with stable CAD undergoing planned CABG surgery on cardiopulmonary bypass using blood cardioplegia.
- Patients aged 21 years and above.
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Heart Centre Singapore Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.